Triamcinolone Acetonide 40 mg/mL · injectable suspension
Steroid, Injections & Implants
OFF-LABELNot in the FDA label for this product
Diabetic macular edema, by intravitreal injection
1 mg or 4 mg intravitreally, repeated at 4-month intervals for persistent edema in the trial
RCT · 840 eyes · laser better
The DRCR Network randomized 840 eyes of 693 patients to focal/grid photocoagulation or to 1 mg or 4 mg preservative-free intravitreal triamcinolone. Acuity was better on 4 mg at 4 months, but by 2 years laser was better than both doses. Intraocular pressure rose by 10 mmHg or more in 4%, 16% and 33% of eyes across the three groups, and cataract surgery was performed in 13%, 23% and 51%. Note the trial used the preservative-free product; Kenalog-40 contains benzyl alcohol and is not formulated for intraocular use.
Contraindications
- Hypersensitivity to any component of the product
- Idiopathic thrombocytopenic purpura, for intramuscular corticosteroid preparations
40 mg/mL in a 1 mL single-dose vial, a 5 mL multiple-dose vial and a 10 mL multiple-dose vial
Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Synthetic analogs such as triamcinolone are primarily used for their anti-inflammatory effects in disorders of many organ systems. KENALOG-40 Injection has an extended duration of effect which may be sustained over a period of several weeks.
Warnings & Precautions
- Epidural and intrathecal neurologic reactions: serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. Arachnoiditis, meningitis, paraparesis/paraplegia, and sensory disturbances have occurred after intrathecal administration. Epidural and intrathecal administration of this product is not recommended.
- Serious neurologic adverse reactions: these epidural events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use.
- Benzyl alcohol toxicity: the product is NOT FOR USE IN NEONATES. Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (hypotension, metabolic acidosis), particularly in neonates, and an increased incidence of kernicterus, particularly in small preterm infants. There have been rare reports of deaths, primarily in preterm infants. With high dosages or other benzyl alcohol medications, consider the daily metabolic load of benzyl alcohol from these combined sources.
- Cataract, glaucoma and ocular infection: corticosteroids may cause posterior subcapsular cataract and glaucoma with possible optic nerve damage, and may enhance secondary ocular infection by bacteria, fungi or viruses. Do not use them in active ocular herpes simplex.
- Optic neuritis recurrence: oral corticosteroids are not recommended for optic neuritis and may raise the risk of new episodes.
- Raised intraocular pressure: intraocular pressure may rise in some patients, so monitor it if steroid therapy continues for more than 6 weeks.
- Endophthalmitis and vision loss with intraocular injection: injection into the eye or the nasal turbinates is not recommended. Endophthalmitis, eye inflammation, increased intraocular pressure and visual disturbances, including vision loss, have been reported with intravitreal use. Intraocular injection of this benzyl alcohol formulation is not recommended because of potential toxicity from the benzyl alcohol.
- Blindness with periocular injection: rare instances of blindness have been associated with periocular injections. Adequate studies of the safety of intraturbinal, subconjunctival, sub-Tenon's, retrobulbar and intraocular (intravitreal) injection have not been performed.
- Anaphylaxis: serious anaphylaxis, including death, has been reported with triamcinolone acetonide injection regardless of the route of administration.
- Local atrophy: unless a deep intramuscular injection is given, local atrophy is likely to occur. Because local atrophy is much more frequent after injection into the deltoid area, avoid that site in favor of the gluteal area.
- Intramuscular or intra-articular use only: the label is headed NOT FOR INTRAVENOUS, INTRADERMAL, INTRAOCULAR, EPIDURAL, OR INTRATHECAL USE. Because KENALOG-40 is a suspension, it should not be given intravenously.
- Increased mortality after cranial trauma: high doses of systemic corticosteroids, including KENALOG-40, should not be used to treat traumatic brain injury. A multicenter, randomized, placebo-controlled trial of the intravenous corticosteroid methylprednisolone hemisuccinate showed higher early (at 2 weeks) and late (at 6 months) mortality in patients with cranial trauma who had no other clear indication for corticosteroid treatment.
- Adrenal insufficiency in stress: KENALOG-40 is a long-acting preparation and is not suitable for use in acute stress situations. Patients on corticosteroid therapy subjected to unusual stress need increased dosage of rapidly acting corticosteroids before, during and after the stressful situation. To avoid drug-induced adrenal insufficiency, supportive dosage may be required in times of stress (such as trauma, surgery, or severe illness) both during treatment and for a year afterwards.
- HPA axis suppression: corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage and may persist for months after discontinuation, so hormone therapy should be reinstituted in any situation of stress during that period. Changes in thyroid status may necessitate adjustment in dosage.
- Impaired mineralocorticoid secretion: when hormone therapy is reinstituted for stress after discontinuation, mineralocorticoid secretion may be impaired, so salt and/or a mineralocorticoid should be administered concurrently.
- Elevation of blood pressure, salt and water retention: average and large doses of corticosteroids can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely with the synthetic derivatives except when they are used in large doses. All corticosteroids increase calcium excretion. Dietary salt restriction and potassium supplementation may be necessary. Use with caution in congestive heart failure, hypertension, or renal insufficiency.
- Cardiac enlargement and congestive heart failure: there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
- Left ventricular free wall rupture: literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction, so use corticosteroids with great caution in these patients.
- Increased risk of infection: corticosteroids suppress the immune system and increase the risk of infection with any pathogen (viral, bacterial, fungal, protozoan, or helminthic) and can mask some signs of infection. These infections can be mild but can be severe and at times fatal, and the rate rises with increasing dosage. Monitor for infection and consider withdrawal or dosage reduction as needed. Do not inject by an intraarticular, intrabursal, or intratendinous route in the presence of acute local infection.
- Tuberculosis reactivation: in patients with latent tuberculosis or tuberculin reactivity, reactivation of the disease may occur, so closely monitor such patients. During prolonged therapy, these patients should receive chemoprophylaxis.
- Varicella and measles: these can have a serious or even fatal course in non-immune patients receiving corticosteroids, so take particular care to avoid exposure. After exposure, prophylaxis with varicella zoster immune globulin (VZIG) for varicella or immunoglobulin (IG) for measles may be indicated; if varicella develops, antiviral treatment may be considered.
- Hepatitis B virus reactivation: this can occur in hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, and infrequently in patients who appear to have resolved hepatitis B infection. Screen for hepatitis B infection before immunosuppressive (e.g., prolonged) treatment, and for patients with evidence of infection recommend consultation with physicians with expertise in managing hepatitis B.
- Systemic fungal infections: corticosteroids may exacerbate systemic fungal infections, so avoid use in the presence of such infections unless needed to control drug reactions. For patients on chronic therapy who develop systemic fungal infections, withdrawal or dosage reduction is recommended.
- Amebiasis: corticosteroids may activate latent amebiasis, so rule out latent or active amebiasis before starting in patients who have spent time in the tropics or patients with unexplained diarrhea.
- Strongyloides hyperinfection: use with great care in known or suspected Strongyloides (threadworm) infestation, where corticosteroid-induced immunosuppression may lead to hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
- Cerebral malaria: avoid corticosteroids, including KENALOG-40, in patients with cerebral malaria.
- Vaccination: administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered, but the response to such vaccines cannot be predicted.
- Kaposi's sarcoma: Kaposi's sarcoma has been reported in patients receiving corticosteroid therapy, most often for chronic conditions, and discontinuation of corticosteroids may result in clinical improvement.
- Gastrointestinal perforation: use steroids with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. Signs of peritoneal irritation after gastrointestinal perforation may be minimal or absent. There is an enhanced effect of corticosteroids in patients with cirrhosis.
- Septic arthritis: intra-articularly injected corticosteroids may be systemically absorbed. Examine any joint fluid to exclude a septic process; a marked increase in pain with local swelling, further restriction of joint motion, fever, and malaise suggests septic arthritis. If the diagnosis of sepsis is confirmed, institute appropriate antimicrobial therapy.
- Joint damage: avoid injection into an infected site. Injection into a previously infected joint is not usually recommended, and injection into unstable joints is generally not recommended. Intra-articular injection may result in damage to joint tissues.
- Osteoporosis and growth inhibition: corticosteroids decrease bone formation and increase bone resorption, which may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Give special consideration to patients at increased risk of osteoporosis (i.e., postmenopausal women) before starting therapy.
- Acute myopathy: an acute myopathy has been observed with high doses of corticosteroids, most often in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) or receiving neuromuscular blocking drugs (e.g., pancuronium). It may involve ocular and respiratory muscles and may result in quadriparesis, and recovery may require weeks to years.
- Psychiatric derangements: these may appear with corticosteroids, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations, and existing emotional instability or psychotic tendencies may be aggravated.
- Dose-dependent complications: complications of treatment with glucocorticoids depend on the size of the dose and the duration of treatment, so make a risk/benefit decision in each case as to dose, duration, and daily or intermittent therapy. Use the lowest possible dose to control the condition, and when dosage reduction is possible, make it gradual.
Common Side Effects
The following adverse reactions may be associated with corticosteroid therapy; the label gives them by body system, without rates. Allergic reactions include anaphylaxis including death, and angioedema. Ophthalmic reactions include exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts and rare instances of blindness associated with periocular injections. Other listed reactions include fluid retention, sodium retention and potassium loss, development of cushingoid state, decreased carbohydrate and glucose tolerance, cutaneous and subcutaneous atrophy, impaired wound healing, osteoporosis, steroid myopathy, peptic ulcer with possible perforation and hemorrhage, mood swings, insomnia and decreased resistance to infection.
Pregnancy: Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose, and animal studies in pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when corticosteroids are administered to a nursing woman.
This product contains benzyl alcohol as a preservative. Benzyl alcohol, a component of this product, has been associated with serious adverse events and death, particularly in pediatric patients. The "gasping syndrome" has been associated with benzyl alcohol dosages >99 mg/kg/day in neonates and low-birth-weight neonates, and premature and low-birth-weight infants may be more likely to develop toxicity. Pediatric patients treated with corticosteroids may experience a decrease in their growth velocity, so monitor linear growth and titrate to the lowest effective dose. Observe pediatric patients with frequent measurements of blood pressure, weight, height and intraocular pressure.